HOME >> MEDICINE >> NEWS
Animal studies indicate new approach for treating end-stage skin and kidney cancers

New Orleans, La., March 26, 2001 Advanced skin and end-stage kidney cancer patients may have a better chance of survival with drugs developed from a new synthetic enzyme that significantly improves the effectiveness of existing interleukin-2 (IL-2) cancer therapy, based on research presented today at the American Association for Cancer Research 92nd Annual Meeting.

In animal studies conducted by researchers at the Huntsman Cancer Institute in Salt Lake City, UT, and MetaPhore Pharmaceuticals in St. Louis, MO, the synthetic enzyme M40403 showed an ability to reverse the extreme blood-pressure drop that is a common side effect of high-dosage IL-2 cancer therapy. The research also showed that the compound enhances the anti-cancer properties of IL-2 therapy.

IL-2 immunotherapy, which works by activating natural killer (NK) cells that have the ability to recognize and destroy many types of tumors, is an approved treatment for inoperable metastatic melanoma and metastatic renal cell carcinoma. About 80,000 cases of melanoma and renal cell carcinoma are diagnosed in the U.S. each year.

IL-2 use is limited, however, by potentially life threatening side effects, including hypotension, particularly at the high-dosage level indicated for these end-stage cancers. A majority of patients undergoing high-dosage IL-2 treatment currently either require intensive care unit (ICU) intervention and/or are unable to complete the full course of treatment.

Reseachers administered the synthetic enzyme, which mimics the action of a natural enzyme, superoxide dismutase (SOD), as a co-therapy with IL-2 in several animal models of advanced cancer. Previous studies have confirmed that the synthetic enzyme effectively reproduces the free-radical fighting properties of the natural SOD enzyme, which has been found to be deficient in cancer states.

When in excess, free radicals particularly superoxide anions have been shown to deactivate a class of molecules, calle
'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
25-Mar-2001


Page: 1 2 3 4

Related medicine news :

1. Animal study shows link between nicotine and atrial flutter
2. Animal studies show stem cells might make biological pacemaker
3. Animal study suggests safer immunization approach to Alzheimers
4. Animal model, new grant, propel UB researchers forward in search for tinnitus treatment
5. Animal model shows early promise for SARS vaccine
6. Understanding Alzheimers disease: Animal research points to new direction for therapy
7. Animal studies prove hormone replacement therapy improves memory, report Pitt researchers
8. Animal-based nutrients linked with higher risk of stomach and esophageal cancers
9. Animal study show that heat-sensitive liposome improves chemotherapy delivery to tumors
10. Animal model shows pain and tissue injury in newborns alters nerve circuitry and reaction to pain later in life
11. AVANT Atherosclerosis Vaccine Raises HDL, Reduces Atherosclerosis In Vaccinated Animals

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... PLEASANT HILL, Calif. (PRWEB) , ... August 13, 2019 , ... ... has welcomed Maria P. Falaschi, vice president of operations and information technology, and Elie ... growing executive team as part of New U Life’s commitment to expanding its corporate ...
(Date:8/14/2019)... ... August 14, 2019 , ... Today, consumers are taking a harder ... impacts their physical body, emotions and energy levels. The trick is finding food and ... , That’s why founder Chris Harper created Chase – a delicious, ...
(Date:8/12/2019)... ... August 12, 2019 , ... Cryotherapy has recently been the target ... Oakland Raiders. However, the cause of Brown’s injury was not due to cryotherapy, but ... session. Numerous NFL teams, such as the Dallas Cowboys, the Washington Redskins, the Denver ...
(Date:8/12/2019)... ... August 12, 2019 , ... Ziegler, a specialty investment ... Bonds for Lesley University, which is currently rated A-/Stable through S&P. Issued through ... used primarily to refund the outstanding debt on the Series 2011 bonds, the ...
(Date:8/12/2019)... ... August 12, 2019 , ... Israeli medical ... significant therapeutic benefits in the use of floristry as treatment for fibromyalgia. ... a total of 61 female fibromyalgia patients participating in a 12-week floral design ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical Trials ... has successfully completed enrollment of 690 patients for a phase III efficacy study ... randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which is ...
(Date:8/15/2019)... SAN RAFAEL, Calif. (PRWEB) , ... August 15, ... ... company, has launched a Private Client service for intended parents who are looking ... is for those fertility patients who are looking for the ultimate concierge service ...
(Date:8/14/2019)... ... August 14, 2019 , ... Canyon ... of 5,217 sf. With pet care at the forefront of design, the project ... endoscopy and CT. Twelve exam rooms, office space and a dedicated grieving space ...
Breaking Medicine Technology:
Cached News: